News

Apexian Pharmaceuticals preclinical studies with APX3330 shuts down inflammatory signaling in leukemia

Indianapolis, IN – December 20, 2018 – An obscure sliver of RNA with a grim-sounding name is unexpectedly taking center stage as a linchpin in transforming pre-leukemic cells into full-blown leukemia.  Apexian Pharmaceuticals’ latest studies in collaboration with Indiana University’s Simon Cancer Center investigator Dr. Reuben Kapur show promise for halting that transformation. These results, published December 6, 2018, in Cell Stem Cell, explain how...

Apexian Pharmaceuticals presents findings at ASH meeting demonstrating APX3330 impact on inflammation and leukemia in preclinical models

Indianapolis, IN – December 12, 2018 – Apexian Pharmaceuticals is shedding light on the question of how pre-leukemic cells transform into full-blown leukemia. Genetic mutations by themselves are rarely enough to flip the switch. Inflammation also plays a role. But, until now, the question of “how” remained unanswered. Apexian Chief Science Officer Mark Kelley, PhD, and his colleagues presented their findings at the American Society...

New Cancer Treatment May Ease Nerves

This article was originally published in the fall 2018 issue of Imagine magazine. Courtesy of Pride of IU website For patients who have just received a cancer diagnosis, the immediate need is clear: battling the life-threatening dangers of the cancer itself. Yet often overshadowed in this fight are the serious side effects of many treatments, which can take a devastating toll on patients’ quality of life....

Apexian Pharmaceuticals presents data on their lead drug for anti-chemotherapy-induced peripheral neuropathy (CIPN), APX3330, at ASCO Palliative Care and Symptom Management meeting

Indianapolis, IN – December 5, 2018 – Chemotherapy causes chemotherapy-induced peripheral neuropathy (CIPN) in a significant number of patients, yet the pharmaceutical landscape is completely devoid of treatments to prevent CIPN. The tingling, burning, pain or numbness in the extremities can limit or stop cancer treatment. And, in half the patients affected, CIPN’s symptoms persist five years or more after treatment ends. Apexian Pharmaceuticals aims...